Latest disclosed round
Series C (second close)
- Date
- 2024-01-02
- Amount
- USD 33.5m
- Sector
- Biotech & techbio
- Companies House
- 13393274
Later stage / growth
Apollo Therapeutics
Pharma/academia JV biopharmaceutical drug discovery
VerifiedSeries C (second close)Cambridge
Evidence status
Directory ready
- Identity
- Verified
- Match
- Verified
- Operating status
- active
- Data origins
- Core directory, Live Chris T D1
Capital network
12 linked investors
AstraZenecaleadCambridge EnterpriseparticipantGSKleadImperial InnovationsparticipantJohnson & Johnson InnovationleadM&G plcparticipantPatient Square CapitalleadReimagined VenturesparticipantRock Springs Capitalparticipanttwo large US public pension plansparticipantUCL BusinessparticipantUCL Technology Fundparticipant
Funding record
4 disclosed rounds
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2024-01-02 | Series C (second close) | $33.5M | M&G plc, Rock Springs Capital, two large US public pension plans |
| 2023-09-06 | Series C | $226.5M | Patient Square Capital, Rock Springs Capital |
| 2021-06-16 | Series B | $145M | Patient Square Capital, Rock Springs Capital, Reimagined Ventures, UCL Technology Fund |
| 2016-01-25 | Formation (JV) | £40M | AstraZeneca, GSK, Johnson & Johnson Innovation, Cambridge Enterprise, Imperial Innovations, UCL Business |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.